biotech / news / / Barchart
Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines.
Bristol-Myers Squibb forecasts 2026 revenue of $46-47.5 billion, surpassing Wall Street estimates.
KEY POINTS
- Management expects Eliquis revenue to grow 10%-15% in 2026 despite Medicare price negotiations.
- The company has already achieved $1 billion from its planned $2 billion cost-cutting initiative.
- BMY shares outperformed the S&P 500 and healthcare ETF XLV year-to-date, rising 8%.
- Consensus analyst rating is 'Moderate Buy' with a mean price target implying 7.8% upside.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →